 Biogen Inc. NASDAQ: BIIB has informed Karyopharm Therapeutics Inc NASDAQ: KPTI that it has opted to terminate the companies Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of. 